Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 4, 2014, Pages 277-283

  Hainsworth, John D ^a,b   Greco, F Anthony ^a,b   Raefsky, Eric L ^b   Thompson, Dana S ^b   Lunin, Scott ^c   Reeves, James ^c   White, Lynn ^a   Quinn, Raven ^a   Debusk, Laura M ^a   Flinn, Ian W ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Tennessee Oncology PLLC   (United States)

^c NONE

Author keywords

Angiogenesis; Anti CD20; Lymphoma; VEGF; VEGF inhibitor

Indexed keywords

BEVACIZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL HEMATOMA; ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; DEMENTIA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HEMATOMA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; WOUND DEHISCENCE; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TREATMENT OUTCOME;

EID: 84904686800     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.02.010     Document Type: Article

References (18)

1. J.D. Hainsworth, S. Litchy, and D.W. Shaffer et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 23 2005 1088 1095
2. B.S. Kahl, F. Hong, and M.E. Williams Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma Blood 2011 118 (abstract 6)
3. F. Bertolini, M. Paolucci, and F. Peccatori et al. Angiogenic growth factors and endostatin in non-Hodgkin lymphoma Br J Haematol 106 1999 504 509
4. N. Niitsu, M. Okamto, and H. Nakamine et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin lymphoma Eur J Haematol 68 2002 91 100
5. P. Salven, A. Orpana, and L. Teerenhovi et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood 96 2000 3712 3718
6. E.S. Wang, J. Teruya-Feldstein, and Y. Wu Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo Blood 104 2004 2893 2902
7. B.D. Cheson, B. Pfistnar, and M.E. Juweid et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
8. M. Ghielmini, S.F. Schmitz, and S.B. Cogliatti et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule Blood 103 2004 4416 4423
9. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
10. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
11. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
12. K.S. Tewari, M. Sill, and H.J. Long et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group J Clin Oncol 2013 31 (abstract 3)
13. F. Mori, T. Ishida, and A. Ito et al. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model Blood Cancer J 2 2012 e67
14. A.T. Stopeck, J.M. Unger, and L.M. Rimsza et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515 Blood 120 2012 1210 1217
15. J.F. Seymour, M. Pfreundshuh, and B. Coiffier et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study Blood 2012 120 (abstract 58)
16. M. Federico, S. Luminari, and A. Dondi et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi J Clin Oncol 31 2013 1506 1513
17. O.W. Press, I.M. Unger, and L.M. Rimsza et al. Phase III randomized Intergroup trial of CHOP plus rituximab combined with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG SW0016 J Clin Oncol 31 2012 314 320
18. M.J. Rumnel, N. Niederle, and G. Mashchmeyer et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet 381 2013 1203 1210